CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Co-Diagnostics, Inc.

CODX
$37M
Micro Cap
NASDAQSurgical & Medical Instruments & Apparatus🇺🇸North AmericaSALT LAKE CITY

Drugs in Pipeline

194

Phase 3 Programs

132

Upcoming Catalysts

15

Next Catalyst

Feb 15, 2026

7d
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

15 upcoming, 1 past

Phase 2Next

MIL62 Phase 2 Results Expected

February 2026~MIL62120

Primary completion for MIL62 trial (NCT05796206) in Systemic Lupus Erythematosus

Source
Phase 2

5-aminolevulinic acid Phase 2 Results Expected

March 2026~5-aminolevulinic acid20

Primary completion for 5-aminolevulinic acid trial (NCT03897491) in Glioblastoma

Source
Phase 2

BL-M07D1 Phase 2 Results Expected

March 2026~BL-M07D142

Primary completion for BL-M07D1 trial (NCT06031584) in Her2-positive/Low-expression Urinary and Digestive Tract Tumors

Source
Phase 2

Test Product HY07121 Phase 2 Results Expected

May 2026~Test Product HY07121258

Primary completion for Test Product HY07121 trial (NCT06639256) in Safety

Source
⭐Phase 3

ELIXCYTE Phase 3 Results Expected

May 2026~ELIXCYTE165

Primary completion for ELIXCYTE trial (NCT05526001) in Knee Osteoarthritis

Source
Phase 2

BL-M07D1 Phase 2 Results Expected

June 2026~BL-M07D1120

Primary completion for BL-M07D1 trial (NCT06445400) in HER2-positive Breast Cancer

Source
Phase 2

BL-B01D1 Phase 2 Results Expected

July 2026~BL-B01D1570

Primary completion for BL-B01D1 trial (NCT06475300) in Non-small Cell Lung Cancer

Source
Phase 2

PD-1 Monoclonal Antibody Phase 2 Results Expected

July 2026~PD-1 Monoclonal Antibody570

Primary completion for PD-1 Monoclonal Antibody trial (NCT06475300) in Non-small Cell Lung Cancer

Source
⭐Phase 3

tapinarof cream, 1% Phase 3 Results Expected

October 2026~Tapinarof cream, 1%58

Primary completion for tapinarof cream, 1% trial (NCT05172726) in Plaque Psoriasis

Source
Phase 2

PD-1 Monoclonal Antibody Phase 2 Results Expected

December 2026~PD-1 Monoclonal Antibody376

Primary completion for PD-1 Monoclonal Antibody trial (NCT06008054) in Esophageal Cancer

Source
Phase 2

BL-B01D1 Phase 2 Results Expected

December 2026~BL-B01D138

Primary completion for BL-B01D1 trial (NCT05924841) in Small Cell Lung Cancer

Source
⭐Phase 3

SKB264 Phase 3 Results Expected

December 2026~SKB264432

Primary completion for SKB264 trial (NCT06711900) in Non-Small Cell Lung Cancer

Source
Phase 2

SI-B003 Phase 2 Results Expected

December 2026~SI-B003130

Primary completion for SI-B003 trial (NCT05965856) in Urothelial Carcinoma

Source
⭐Phase 3

pemetrexed Phase 3 Results Expected

December 2026~pemetrexed432

Primary completion for pemetrexed trial (NCT06711900) in Non-Small Cell Lung Cancer

Source
Phase 2

BL-M07D1 Phase 2 Results Expected

December 2026~BL-M07D1138

Primary completion for BL-M07D1 trial (NCT06131450) in Gynecological Malignancies

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

MK0653A, ezetimibe (+) simvastatin

Phase 3

Hypercholesterolemia

Cilostazol

Phase 3

Vasospastic Angina

SEP-363856

Phase 3

Schizophrenia

OPC-34712FUM/ Brexpiprazole fumarate

Phase 3

Schizophrenia

Tolvaptan

Phase 3

Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Nalmefene hydrochloride

Phase 3

Alcohol Dependence

EPs® 7630

Phase 3

Common Cold

NOMAC-E2

Phase 3

Contraception

MK0476, montelukast sodium

Phase 3

Rhinitis, Allergic, Seasonal

ezetimibe (+) simvastatin

Phase 3

Cardiovascular Disorder

WO3970

Phase 3

Primary Axillary Hyperhidrosis

Rescue medication

Phase 3

Bipolar Disorder

MK0954, /Duration of Treatment : 16 Weeks

Phase 3

Hypertension

Olanzapine

Phase 3

Bipolar Disorder

Simvastatin 20 mg

Phase 3

Hypercholesterolemia

Ciprofol

Phase 3

Gynecological Outpatient Surgery

HSK7653 25 mg Q2W

Phase 3

Diabetes Mellitus, Type 2

valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

Phase 3

Hypertension

ezetimibe with simvastatin

Phase 3

Hypercholesterolemia

recombinant birch pollen allergen

Phase 3

Allergy

HSK7653 10 mg Q2W

Phase 3

Diabetes Mellitus, Type 2

HSK3486

Phase 3

Induction and Maintenance of General Anesthesia

ADC189 tablets

Phase 3

Influenza Type A

VC005 tablets

Phase 3

Non-segmental Vitiligo

Rizatriptan 5 mg

Phase 3

Migraine Disorders

Ezetimibe

Phase 3

Hypercholesterolemia

SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )

Phase 3

Asthma

SKB264

Phase 3

Non-small Cell Lung Cancer

mometasone furoate combination MDI 200/10 mcg BID

Phase 3

Asthma

MK0663, etoricoxib / Duration of Treatment: 6 Weeks

Phase 3

Osteoarthritis

Tapinarof cream, 1%

Phase 3

Plaque Psoriasis

Desloratadine 5 mg

Phase 3

Perennial Allergic Rhinitis

5-mg Desloratadine

Phase 3

Allergic Rhinitis

MR308

Phase 3

Acute Pain

Shugan Jieyu Capsules

Phase 3

Generalized Anxiety Disorder

simvastatin (+) ezetimibe

Phase 3

Hypercholesterolemia

OPA-15406

Phase 3

Atopic Dermatitis

daptomycin

Phase 3

Pneumonia, Bacterial

Montelukast Oral Granules (OG)

Phase 3

Perennial Allergic Rhinitis

Osimertinib

Phase 3

Non-small Cell Lung Cancer

loratadine; montelukast

Phase 3

Rhinitis, Allergic, Seasonal

Tetravalent influenza virus lysis vaccine

Phase 3

Coronavirus Disease 2019

Tibolone

Phase 3

Osteoporosis

Liposomal doxorubicin, Paclitaxel or Topotecan

Phase 3

Epithelial Ovarian Cancer

BL-B01D1

Phase 3

Small Cell Lung Cancer

Tramadol

Phase 3

Acute Pain

Allerslit forte

Phase 3

Allergy

MK0653, ezetimibe

Phase 3

Lipid Metabolism, Inborn Errors

rolofylline

Phase 3

Heart Failure, Congestive

allo-APZ2-CVU

Phase 3

Skin Ulcer Venous Stasis Chronic

OPC-34712

Phase 3

Schizophrenia

TEV-48125

Phase 3

Migraine

alendronate

Phase 3

Paget's Disease of Bone

Atorvastatin 10 mg

Phase 3

Hypercholesterolemia

Oxycodone

Phase 3

Cancer

methylphenidate hydrochloride

Phase 3

Attention Deficit Hyperactivity Disorder

losartan potassium (+) hydrochlorothiazide

Phase 3

Hypertension

rizatriptan benzoate

Phase 3

Acute Migraine With or Without Aura in Adolescents

Ezetimibe 10 mg

Phase 3

Hypercholesterolemia

SCH 900962 / Corifollitropin alfa / Org 36286

Phase 3

Infertility

Oxycodone nalaxone prolonged release tablets (OXN)

Phase 3

Pain

MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks

Phase 3

Osteoporosis

Corifollitropin alfa

Phase 3

Hypogonadotropic Hypogonadism

Surotomycin

Phase 3

Clostridium Difficile Infection

MK0217, alendronate sodium / Duration of Treatment : 2 Years

Phase 3

Osteoporosis, Postmenopausal

EZ 10 mg/Atorva 20 mg FDC

Phase 3

Hypercholesterolemia

Propofol

Phase 3

Sedation in Intensive Care

MK0663, etoricoxib

Phase 3

Osteoarthritis

Grass pollen allergens in a water/glycerol solution

Phase 3

Allergic Rhinoconjunctivitis

Eptifibatide (Integrilin)

Phase 3

Myocardial Ischemia

simvastatin

Phase 3

Hypercholesterolemia

ELIXCYTE

Phase 3

Knee Osteoarthritis

Allergovit 6-grasses

Phase 3

Grass Pollen Allergy

Hetrombopag

Phase 3

Immune Thrombocytopenia

wasp venom

Phase 3

Allergy

Grass pollen specific immunotherapy

Phase 3

Rhinoconjunctivitis

KHK4827

Phase 3

Moderate to Severe Plaque Psoriasis

180mg of ETC-1002(bempedoic acid)

Phase 3

Hypercholesterolemia

MK0462, rizatriptan benzoate / Duration of Treatment -1day

Phase 3

Migraine

semaglutide injection

Phase 3

Diabetes Mellitus, Type 2

AL0704rP

Phase 3

Rhinoconjunctivitis

Tibolone 2.5 mg

Phase 3

Postmenopausal Women

bee venom

Phase 3

Bee Venom Allergy

Grass pollen formulation

Phase 3

Grass Pollen Allergy

Recombinant birch pollen

Phase 3

Birch Pollen Allergy

Acaroid

Phase 3

Respiratory Hypersensitivity

specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)

Phase 3

Rhinoconjunctivitis

ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm

Phase 3

Tuberculosis

desloratadine

Phase 3

Chronic Idiopathic Urticaria

Thioctic Acid

Phase 3

Diabetic Polyneuropathy

CARTISTEM

Phase 3

Degenerative Osteoarthritis

Recombinant Mycobacterium Tuberculosis Fusion Protein

Phase 3

Latent Tuberculosis Infection

Sotatercept

Phase 3

Pulmonary Arterial Hypertension

ibandronate

Phase 3

Postmenopausal Osteoporosis

pemetrexed

Phase 3

Non-Small Cell Lung Cancer

Tafasitamab

Phase 3

DLBCL

MK0663, Etoricoxib / Duration of Treatment : 12 Weeks

Phase 3

Recurrent Low Back Pain

HSK21542

Phase 3

Pruritus

Bacillus Calmette - Guerin

Phase 3

Tuberculosis

Fidaxomicin

Phase 3

Clostridium Infections

FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)

Phase 3

Osteoporosis

Atorvastatin

Phase 3

Hypercholesterolemia

Salmeterol xinafoate

Phase 3

Exercise Induced Asthma

HSK21542 Injection

Phase 3

Postoperative Analgesia

Birch pollen allergoid

Phase 3

Pollen Allergy

Etoricoxib 90 mg

Phase 3

Pain, Postoperative

MK0653A (ezetimibe [+] simvastatin)

Phase 3

Hypercholesterolemia

Asenapine 5 mg

Phase 3

Schizophrenia

Lasmiditan 50mg

Phase 3

Acute Migraine

MK-0954A

Phase 3

Hypertension

Hydronidone capsules

Phase 3

Liver Fibrosis

CXA-201

Phase 3

Complicated Urinary Tract Infection

Montelukast

Phase 3

Rhinitis, Allergic, Perennial

MK0217, /Duration of Treatment : 12 Months

Phase 3

Osteoporosis, Postmenopausal

Mometasone furoate nasal spray (MFNS)

Phase 3

Rhinitis, Allergic

Meplazumab for injection

Phase 3

Post-COVID-19

MK0954, /Duration of Treatment : 5 Years

Phase 3

Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

Asenapine

Phase 3

Psychosis

Losartan Potassium

Phase 3

Proteinuria

Recombinant grass pollen

Phase 3

Allergy

montelukast sodium

Phase 3

Asthma

Vehicle Cream

Phase 3

Atopic Dermatitis

Tapinarof

Phase 3

Plaque Psoriasis

Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID

Phase 3

Asthma

MK0733 / Duration of Treatment: 18 Weeks

Phase 3

HDL Cholesterol

MK0906, finasteride / Duration of Treatment: 48 weeks

Phase 3

Benign Prostatic Hyperplasia

Aripiprazole

Phase 3

Bipolar I Disorder

Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program

Phase 3

Rabies Vaccine Adverse Reaction

OPC-41061

Phase 3

Cirrhosis

Brexpiprazole

Phase 3

Agitation Associated With Dementia of the Alzheimer's Type

SPM 962

Phase 3

Parkinson's Disease

OPC-41061(Tolvaptan)

Phase 3

Heart Failure, Congestive

E6011 2 mg/kg

Phase 2

Crohn's Disease

Palonosetron

Phase 2

Nausea

SHR-1210

Phase 2

Small-cell Lung Cancer

Ganirelix

Phase 2

Controlled Ovarian Stimulation

MIL62

Phase 2

Systemic Lupus Erythematosus

ALC-2203-1

Phase 2

Acute Bronchitis

BL-M07D1

Phase 2

HER2-positive Breast Cancer

Ecallantide

Phase 2

Bloodloss

KUS121 high dose

Phase 2

Central Retinal Artery Occlusion

Org 36286

Phase 2

Infertility

ABSK061 + ABSK043

Phase 2

HER2-Gastric/Gastroesophageal Junction Cancer

PTA + Infusion of MSC_Apceth

Phase 2

Critical Limb Ischemia

Sotatercept 0.3 mg/kg

Phase 2

Hypertension, Pulmonary

Oxycodone naloxone prolonged release tablets

Phase 2

Interstitial Cystitis

Dalantercept

Phase 2

Squamous Cell Carcinoma of the Head and Neck

MK-3795

Phase 2

VHL Gene Mutation

E6007

Phase 2

Moderate Active Ulcerative Colitis

JAB-21822 (KRAS G12C inhibitor)

Phase 2

Advanced Solid Tumor

HSK31679 80mg

Phase 2

Non-Alcoholic Steatohepatitis (NASH)

Biological: AL0206st

Phase 2

Rhinoconjunctivitis

ARQ 197

Phase 2

Non Small Cell Lung Cancer

Luspatercept

Phase 2

Anemia

Pneumostem®

Phase 2

Bronchopulmonary Dysplasia

mometasone furoate/formoterol 100/10 mcg

Phase 2

Asthma

Human Heterologous Liver Cells

Phase 2

Urea Cycle Disorders

rebamipide

Phase 2

Colitis, Ulcerative

rBet v1-FV

Phase 2

Allergic Rhinoconjunctivitis

Human umbilical cord blood-derived mesenchymal stem cells

Phase 2

Acute Leukemia

rPhleum

Phase 2

Type I-Allergy

5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm

Phase 2

Tuberculosis

Tivantinib

Phase 2

Advanced Solid Tumors

TNTL capsule

Phase 2

Accidental Exposure While Preparing Drug for Administration

PNEUMOSTEM

Phase 2

Severe Bronchopulmonary Dysplasia

PD P 506 A

Phase 2

Onychomycosis

HSK3486 0.1-0.2 /0.3 mg / kg group

Phase 2

Sedation

Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

Phase 2

COVID-19

etonogestrel with testosterone undecanoate

Phase 2

Contraception

PD-1 Monoclonal Antibody

Phase 2

Non-small Cell Lung Cancer

Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

Phase 2

Rheumatoid Arthritis

TLL018 tablets

Phase 2

Plaque Psoriasis

Recombinant new coronavirus vaccine (CHO cell)

Phase 2

COVID-19

SB011, 2 % (Water/Oil/Water) emulsion of hgd40

Phase 2

Mild to Moderate Atopic Dermatitis

OXN PR followed by OxyPR tablets

Phase 2

Severe Chronic Pain

Sugar Pill

Phase 2

Osteoarthritis of the Knee

Tangning Tongluo Capsule

Phase 2

General Disorders and Administration Site Conditions

Test Product HY07121

Phase 2

Safety

SI-B003

Phase 2

Urothelial Carcinoma

Test Product HYP-6589

Phase 2

Solid Tumor

5-aminolevulinic acid

Phase 2

Glioblastoma

Dimethicone

Phase 2

Scalp Psoriasis

HSK39297 200mgQD

Phase 2

Lupus Nephritis (LN)

Recombinant novel coronavirus vaccine (CHO cells)

Phase 2

Prevention of COVID-19

Formatris 24µg

Phase 2

Asthma

MT1013

Phase 2

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Oxycodone Naloxone

Phase 2

Moderate to Severe Pain Due to Diabetic Polyneuropathy

JAB-23E73

Phase 2

Advanced Solid Tumor

OG-6219

Phase 2

Endometriosis

Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)

Phase 2

Seasonal Allergic Rhinitis

Gefapixant

Phase 2

Idiopathic Pulmonary Fibrosis

HSK39004 Dry Powder Inhaler -0.75mg BID

Phase 2

Chronic Obstructive Lung Disease (COLD)

HSK16149 20mg BID

Phase 2

Diabetic Peripheral Neuropathic Pain

Etoricoxib 75 mg 4% DMSO Gel

Phase 2

Osteoarthritis Pain

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
CODX News